Article Text

Download PDFPDF
Randomised controlled trial
Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes
  1. Sheila A Doggrell
  1. Correspondence to: Dr Sheila A Doggrell, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4002, Australia; sheila.doggrell{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Despite the treatments available for type 2 diabetes, about two-thirds of these patients die from associated heart disease or stroke.1 Approval of the first glucagon-like peptide-1 agonist (GLP-1), exenatide, by the FDA in 2005 generated an expectation that the clinical outcomes in type 2 diabetes would be improved. However, we still do not have definitive evidence that exenatide does this, although a clinical trial to determine this, the Exenatide Study of Cardiovascular Even Lowering (EXSCEL) trial, is under way.2 Subsequently, other GLP-1 receptor agonists, including liraglutide, have also been approved and used for 10 years without clinical outcome data.3 Recently, the results of Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.